Message #9 From:
TheMachine Date: September 19, 2008 03:50:49 AM
Re: glioblastoma multiforme
We need to stop this cancer. I hope Lixte Biotechnology, Inc. is a cure.
Lixte Biotechnology Holdings, Inc. (Lixte) is
a cancer therapeutics and diagnostics company dedicated to bringing
improved treatments of human cancers to clinical practice.
Lixte recognizes that competing effectively at the highest level of
drug development and creating a successful cancer therapeutics company
requires access to multiple highly specialized types of expertise.
These disciplines include scientific (molecular and biology,
proteomics, biochemistry, chemistry, pharmacology, physiology, and
toxicology) financial, regulatory, legal and administrative skills.
Lixte’s strategy is to leverage its intellectual resources by acquiring
access to the necessary expert knowledge and technical capabilities in
each of these disciplines through scientific academic and commercial
collaborations, incentivized consultants and advisors, and the purchase
of specific technical services rather than by investing in an
enormously expensive in-house employee and technical infrastructure
that is likely to continuously need modification.
Since February, 2006 we have filed four patent applications on the
nature and uses of proprietary lead compounds of two distinct classes
of drugs having activity against several types of human cancers in the
test tube and, in the case of gliobastoma multiforme, the most common
and almost uniformly fatal brain tumor of adults, activity in an animal
model. http://www.lixte.com/aboutLIXTE.html Read up on it. Spread the word.
